Stockscreener 앱 받기
0.2716
1.24%
-0.0034
전일 마감가:
$0.275
열려 있는:
$0.2873
하루 거래량:
505.38K
Relative Volume:
0.07
시가총액:
$46.84M
수익:
$49.09M
순이익/손실:
$-52.15M
주가수익비율:
-0.4178
EPS:
-0.65
순현금흐름:
$-45.93M
1주 성능:
-1.84%
1개월 성능:
-9.65%
6개월 성능:
-81.65%
1년 성능:
-83.02%
1일 변동 폭
$0.27
$0.29
1주일 범위
$0.2503
$0.305
52주 변동 폭
$0.1718
$2.04
바이오데식스 Stock (BDSX) Company Profile
명칭
Biodesix Inc
전화
303-417-0500
주소
919 WEST DILLON ROAD, LOUISVILLE
BDSX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
0.2716 | 46.84M | 49.09M | -52.15M | -45.93M | -0.65 |
|
TMO
Thermo Fisher Scientific Inc
|
429.33 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
203.20 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
547.01 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
121.38 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
164.24 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
바이오데식스 Stock (BDSX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-09-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-07-26 | 개시 | Craig Hallum | Buy |
| 2024-05-13 | 개시 | TD Cowen | Buy |
| 2024-05-03 | 개시 | Lake Street | Buy |
| 2021-11-17 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-23 | 개시 | BTIG Research | Buy |
| 2020-11-23 | 개시 | Canaccord Genuity | Buy |
| 2020-11-23 | 개시 | Morgan Stanley | Overweight |
| 2020-11-23 | 개시 | William Blair | Outperform |
모두보기
바이오데식스 주식(BDSX)의 최신 뉴스
Biodesix, Inc. (NASDAQ:BDSX) Short Interest Up 127.0% in May - Defense World
Biodesix, Inc. (NASDAQ:BDSX) Stock Rockets 30% But Many Are Still Ignoring The Company - simplywall.st
Millennium Management LLC Buys 33,329 Shares of Biodesix, Inc. (NASDAQ:BDSX) - Defense World
Biodesix (BDSX) Partners with APAPP to Enhance Lung Cancer Care - GuruFocus
Biodesix, Inc. Partners with Association of Pulmonary Advanced Practice Providers to Deliver Nation's First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs - MarketScreener
Biodesix Partners with Association of Pulmonary Advanced Practic - GuruFocus
Biodesix partners with Association of Pulmonary APPs for lung cancer education - TipRanks
Public market insider buying at Freehold Royalties (FRU) - The Globe and Mail
Biodesix Partners with Association of Pulmonary Advanced - GlobeNewswire
Biodesix Partners with APAPP to Enhance Lung Cancer Education and Access to Diagnostic Tools - Nasdaq
Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation’s First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs - Yahoo
Jane Street Group LLC Acquires New Holdings in Biodesix, Inc. (NASDAQ:BDSX) - Defense World
Wall Street’s big rally stalls following some discouraging economic data - The Globe and Mail
Biodesix at 45th Annual William Blair Growth Stock Conference: Lung Health Focus - Investing.com Canada
Northern Trust Corp Grows Stake in Biodesix, Inc. (NASDAQ:BDSX) - Defense World
Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting - The Manila Times
Scotiabank Has Lowered Expectations for Biodesix (NASDAQ:BDSX) Stock Price - Defense World
Biodesix Announces New Data on the VeriStrat® Test to be Present - GuruFocus
Biodesix to Present New Data on Host Immune Classifier for NSCLC at 2025 ASCO Annual Meeting - Nasdaq
Game-Changing Cancer Test Triples Survival Rate: New Clinical Data Transforms Lung Cancer Treatment - Stock Titan
Independent Director of Biodesix Picks Up 15% More Stock - Yahoo Finance
Biodesix (BDSX) Target Price Reduced to $2 by Scotiabank | BDSX Stock News - GuruFocus
Biodesix Jumps 46% As Insider Buying, Retail Optimism Offset Scotiabank Target Cut By Stocktwits - Investing.com India
Biodesix Jumps 46% As Insider Buying, Retail Optimism Offset Scotiabank Target Cut - MSN
Scotiabank cuts Biodesix stock target to $2, maintains outlook By Investing.com - Investing.com Canada
Biodesix Approves Reverse Stock Split at Annual Meeting - TipRanks
Scotiabank cuts Biodesix stock target to $2, maintains outlook - Investing.com
Biodesix (BDSX) Sees Target Price Lowered by Scotiabank | BDSX S - GuruFocus
Biodesix (BDSX) Sees Target Price Lowered by Scotiabank | BDSX Stock News - GuruFocus
Biodesix price target lowered to $2 from $3 at Scotiabank - TipRanks
Biodesix to Participate in Upcoming Investor Conferences | BDSX Stock News - GuruFocus
Biodesix to Participate in Upcoming Investor Conferences - GlobeNewswire
Biodesix Executives Set for Major Investor Conferences: William Blair and Craig-Hallum Presentations Ahead - Stock Titan
What's Behind The Big Stock Moves? BDSX, APLM, RNAZ... - Nasdaq
Director’s Massive Stock Purchase Signals Confidence in Biodesix! - TipRanks
Biodesix, Inc. (NASDAQ:BDSX) Shares Bought by Cubist Systematic Strategies LLC - Defense World
Biodesix's (BDSX) "Market Perform" Rating Reaffirmed at William Blair - MarketBeat
Craig Hallum Cuts Biodesix (NASDAQ:BDSX) Price Target to $1.50 - Defense World
William Blair Has Bearish Estimate for Biodesix Q2 Earnings - Defense World
Biodesix revises 2025 revenue guidance to $80M–$85M amid sales force reconfiguration and primary care expansion - MSN
Susquehanna International Group LLP Grows Stock Holdings in Biodesix, Inc. (NASDAQ:BDSX) - MarketBeat
Biodesix, Inc. (NASDAQ:BDSX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Yahoo Finance
Biodesix, Inc. Earnings Call: Growth Amid Challenges - TipRanks
Biodesix, Inc. (NASDAQ:BDSX) Q1 2025 Earnings Call Transcript - MSN
Analysts Just Slashed Their Biodesix, Inc. (NASDAQ:BDSX) EPS Numbers - simplywall.st
Biodesix Announces New Clinical and Economic Data for Its Nodify Lung® Tests At ISPOR and ATS - marketscreener.com
News Flash: 6 Analysts Think Biodesix, Inc. (NASDAQ:BDSX) Earnings Are Under Threat - Yahoo Finance
Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS | BDSX Stock News - GuruFocus
Biodesix, Inc. to Present New Data on Lung Cancer Diagnosis and Testing at ISPOR and ATS 2025 Conferences - Nasdaq
Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS - GlobeNewswire
New Clinical Data: Biodesix Lung Cancer Tests Could Prevent 60% of Unnecessary Invasive Procedures - Stock Titan
바이오데식스 (BDSX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오데식스 주식 (BDSX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| SCHULER JACK W | Director |
May 19 '25 |
Buy |
0.34 |
723,239 |
246,624 |
20,918,174 |
| Vazquez Chris | Chief Accounting Officer |
May 12 '25 |
Sale |
0.36 |
112 |
40 |
18,113 |
| Vazquez Chris | Chief Accounting Officer |
May 13 '25 |
Sale |
0.35 |
112 |
40 |
18,001 |
| Pestano Gary Anthony | Chief Development Officer |
May 12 '25 |
Sale |
0.36 |
223 |
80 |
157,163 |
| Pestano Gary Anthony | Chief Development Officer |
May 13 '25 |
Sale |
0.35 |
222 |
78 |
156,941 |
| O'Kane Kieran | Chief Commercial Officer |
May 12 '25 |
Sale |
0.36 |
239 |
86 |
139,290 |
| O'Kane Kieran | Chief Commercial Officer |
May 13 '25 |
Sale |
0.35 |
238 |
84 |
139,052 |
| Hutton Scott | President & CEO |
May 12 '25 |
Sale |
0.36 |
1,888 |
679 |
722,271 |
| Hutton Scott | President & CEO |
May 13 '25 |
Sale |
0.35 |
1,887 |
666 |
720,384 |
| Cowie Robin Harper | CFO, Sec'y & Treasurer |
May 12 '25 |
Sale |
0.36 |
496 |
178 |
249,121 |
0.18%
0.48%
자본화:
|
볼륨(24시간):